Summary
There is an ever-increasing demand for MCMs across the world.
BioThrax continues to be a key growth driver for Emergent BioSolutions in 2018.
The company boasts of a robust research pipeline.
Acquisitions are also playing a key role in strengthening Emergent BioSolutions' product portfolio.
Certain risks cannot be ignored by retail investors.
Emergent BioSolutions (EBS) is a specialty pharmaceutical company and offers products to governments and healthcare providers for tackling with accidental, natural, and intentional public threats. These threats involve chemical, biological, explosive, radiological/nuclear, and emerging infectious disease threats.
These are precarious times and the increasing incidence of public threats, both by state and non-state actors, across the globe, has spurred up the governments across the world to focus on medical countermeasures or MCMs. In this context, Emergent BioSolutions can leverage its solid position in the MCM segment and especially in biodefense area to rapidly advance its financial position.
In this article, I will explain why I believe Emergent BioSolutions is a promising pick for 2018.
